Last reviewed · How we verify
Aldara 5% Topical Cream
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions.
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions. Used for Actinic keratosis, Basal cell carcinoma (superficial), Genital warts (external).
At a glance
| Generic name | Aldara 5% Topical Cream |
|---|---|
| Also known as | Zyclara, imiquimod |
| Sponsor | University Medical Centre Maribor |
| Drug class | Toll-like receptor 7 (TLR7) agonist |
| Target | TLR7 |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Oncology |
| Phase | Phase 3 |
Mechanism of action
Imiquimod binds to TLR7 on immune cells, triggering production of interferon-alpha and other cytokines that enhance local immune activation. This stimulates both innate and adaptive immune responses against abnormal skin cells, leading to clearance of lesions. The topical formulation concentrates immune activation at the site of application.
Approved indications
- Actinic keratosis
- Basal cell carcinoma (superficial)
- Genital warts (external)
Common side effects
- Local skin irritation (erythema, erosion)
- Pruritus
- Scabbing/crusting
- Flu-like symptoms (systemic)
- Local edema
Key clinical trials
- Topical Imiquimod Treatment of Oral Dysplasia (PHASE1, PHASE2)
- Basal Cell Carcinoma Chemoprevention Trial (PHASE3)
- Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma (PHASE1, PHASE2)
- A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (PHASE1)
- Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC (PHASE1)
- Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia (PHASE4)
- Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme (PHASE1, PHASE2)
- Neoadjuvant Imiquimod Immunotherapy for Oral Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aldara 5% Topical Cream CI brief — competitive landscape report
- Aldara 5% Topical Cream updates RSS · CI watch RSS
- University Medical Centre Maribor portfolio CI